Swiss-headquartered CDMO Lonza has strengthened its advanced synthesis capabilities to broaden support for the discovery and development of ADCs and other bioconjugates at its site in Oss, the Netherlands.
The expansion includes the full integration of the ADC technology platform that Lonza acquired through its purchase of Synaffix in 2023. The platform brings together antibody conjugation technology, polar spacer technology, and a linker payload portfolio. Lonza states that these clinically validated, site-specific technologies are intended to improve the efficacy and tolerability of ADCs.
The platform has also been updated to incorporate dual-payload ADC technology, which allows two complementary cytotoxic agents to be attached to a single antibody with adjustable payload ratios. According to the company, this approach aims to tackle tumor heterogeneity and drug resistance, drawing on Lonza's end-to-end development and manufacturing expertise spanning early discovery through to clinical supply.
In addition, Lonza has invested in expanding the Oss site with new laboratory infrastructure, additional scientific staff, and greater R&D capacity to accommodate ADCs and emerging bioconjugate modalities, such as antibody-oligonucleotide conjugates, targeted lipid nanoparticles, and protein-protein conjugates. The site now offers a combination of small-scale bioconjugate prototyping services and scale-up capabilities for pilot toxicology material, supported by on-site process and analytical development.
In a related development from last month, Synaffix and Sidewinder Therapeutics announced a multi-target licensing agreement giving Sidewinder access to the site-specific ADC platform to advance its bispecific ADC pipeline for solid tumors. The agreement covers use of the conjugation, spacer, and linker-payload technologies across Sidewinder's bispecific antibody programs.
Bron: Pharmamanufacturing.com